Crossmark

Leucine-rich alpha-2-glycoprotein 1 (LRG1) decrement during biologics therapy and its correlation with disease features and treatment outcomes in rheumatoid arthritis patients

Crossref DOI link: https://doi.org/10.1007/s10067-025-07545-2

Published Online: 2025-07-15

Published Print: 2025-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zou, Liang https://orcid.org/0009-0000-2101-0521
Fan, Qiuyu

Liu, Ya

He, Hao

Jia, Chao
License Information

Text and Data Mining valid from 2025-07-15

Version of Record valid from 2025-07-15
More Information

Article History

Received: 24 December 2024

Revised: 31 May 2025

Accepted: 16 June 2025

First Online: 15 July 2025

Declarations

:

: All procedures have been approved by the ethics committee of Wuhan No.1 Hospital and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: All participants signed the informed consent.

: None.

Document is current

Any future updates will be listed below